3D Echo Characterization of Proportionate and Disproportionate Functional Mitral Regurgitation before and after Percutaneous Mitral Valve Repair.
EROA/LVEDV ratio
MitraClip
PMVr
disproportionate MR
functional mitral regurgitation
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Jan 2022
27 Jan 2022
Historique:
received:
03
12
2021
revised:
20
01
2022
accepted:
24
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
The impact of percutaneous mitral valve repair (PMVr) on long-term prognosis in patients with functional mitral regurgitation (FMR) is still unclear. Recently, a new conceptual framework classifying FMR as proportionate (P-MR) and disproportionate (D-MR) was proposed, according to the effective regurgitant orifice area/left ventricular end-diastolic volume (EROA/LVEDV) ratio. The aim was to assess its possible influence on PMVr efficacy. A total of 56 patients were enrolled. MV annulus, LV volumes and function were assessed. Global longitudinal strain (GLS) was also calculated. Patients were divided into two groups, according to the EROA/LVEDV ratio. Echocardiographic follow-up was performed after 6 months, and adverse events were collected after 12 months. D-MR patients (n = 28, 50%) had a significantly more elliptical MV annulus ( Patients with P-MR seem to have worse outcomes after PVMr than D-MR patients. Our study confirms the importance of the EROA/LVEDV ratio in defining different subsets of FMR based on the anatomical characteristic of MV and LV.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of percutaneous mitral valve repair (PMVr) on long-term prognosis in patients with functional mitral regurgitation (FMR) is still unclear. Recently, a new conceptual framework classifying FMR as proportionate (P-MR) and disproportionate (D-MR) was proposed, according to the effective regurgitant orifice area/left ventricular end-diastolic volume (EROA/LVEDV) ratio. The aim was to assess its possible influence on PMVr efficacy.
METHODS
METHODS
A total of 56 patients were enrolled. MV annulus, LV volumes and function were assessed. Global longitudinal strain (GLS) was also calculated. Patients were divided into two groups, according to the EROA/LVEDV ratio. Echocardiographic follow-up was performed after 6 months, and adverse events were collected after 12 months.
RESULTS
RESULTS
D-MR patients (n = 28, 50%) had a significantly more elliptical MV annulus (
CONCLUSIONS
CONCLUSIONS
Patients with P-MR seem to have worse outcomes after PVMr than D-MR patients. Our study confirms the importance of the EROA/LVEDV ratio in defining different subsets of FMR based on the anatomical characteristic of MV and LV.
Identifiants
pubmed: 35160100
pii: jcm11030645
doi: 10.3390/jcm11030645
pmc: PMC8836818
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA Cardiol. 2017 Oct 1;2(10):1130-1139
pubmed: 28877291
EuroIntervention. 2016 Apr 20;11(13):1554-61
pubmed: 26348680
N Engl J Med. 2018 Dec 13;379(24):2297-2306
pubmed: 30145927
Catheter Cardiovasc Interv. 2019 May 1;93(6):1152-1160
pubmed: 30790417
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
J Am Coll Cardiol. 2005 Dec 6;46(11):2134-40
pubmed: 16325053
JACC Cardiovasc Imaging. 2019 Feb;12(2):353-362
pubmed: 30553663
J Am Coll Cardiol. 2015 Jul 21;66(3):278-307
pubmed: 26184622
Circulation. 2019 Jan 2;139(1):37-47
pubmed: 30586701
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Eur J Cardiothorac Surg. 2017 Oct 1;52(4):616-664
pubmed: 29156023
J Heart Valve Dis. 2016 Jul;25(4):475-482
pubmed: 28009952
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
JAMA Cardiol. 2020 Apr 1;5(4):469-475
pubmed: 32074243
J Am Coll Cardiol. 2012 Jan 10;59(2):130-9
pubmed: 22222076
JACC Cardiovasc Imaging. 2021 Apr;14(4):742-752
pubmed: 32950444
Eur Heart J. 2019 Jul 14;40(27):2203-2205
pubmed: 31219554
Int J Cardiol Heart Vasc. 2018 Nov 19;22:18-19
pubmed: 30505928
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Cardiology. 2020;145(2):110-120
pubmed: 31794963
JACC Cardiovasc Imaging. 2021 Apr;14(4):715-725
pubmed: 32861652
Eur Heart J Cardiovasc Imaging. 2019 Jun 1;20(6):620-624
pubmed: 31115470
J Am Coll Cardiol. 2012 May 15;59(20):1799-808
pubmed: 22575319
J Am Coll Cardiol. 2009 Aug 18;54(8):686-94
pubmed: 19679246
Eur Heart J. 2018 Jan 1;39(1):39-46
pubmed: 29020337
J Am Soc Echocardiogr. 2017 Nov;30(11):1049-1058
pubmed: 28916243
J Cardiovasc Med (Hagerstown). 2019 Oct;20(10):701-708
pubmed: 31343448
Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):611-44
pubmed: 23733442
J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e75-e79
pubmed: 29538148
Eur Heart J Cardiovasc Imaging. 2019 May 1;20(5):558-564
pubmed: 30412229